CommercialPrior AuthHigh impact
Bevacizumab Products (Avastin®; Mvasi® ; Zirabev™; Alymsys®; Vegzelma™, Avzivi®, Jobevne™)
BCBS Tennessee·Oncology, Ophthalmology, Hematology·Medical Policy
Effective date
Jul 31, 2026
We identified it
Jun 17, 2026
Summary
Fresh policy update covering bevacizumab products (Avastin and biosimilars) for cancer treatment and ophthalmic disorders. This comprehensive policy establishes coverage criteria with 6-month authorizations for eye conditions and 12-month authorizations for various cancers, with step therapy requirements for some specialty medications.
Action Required
Before July 31, 2026: Billing team must implement prior authorization requirements for all bevacizumab products (Avastin, Mvasi, Zirabev, Alymsys, Vegzelma, Avzivi, Jobevne). Update authorization tracking to request 6-month approvals for ophthalmic disorders and 12-month approvals for oncology indications. Review step therapy requirements document at bcbst.com for provider-administered specialty medications. Claims without proper authorization will be denied.